psychopharmacology • antipsychotics • antiepileptics • antidepressants • tardive dyskinesia • anxiolytics • therapeutics
My research focuses on multicenter randomized clinical trials to study the efficacy and tolerability of new add-on treatments in patients with persistent, predominant negative symptoms of schizophrenia and patients with sub-optimally controlled symptoms of schizophrenia. These new add-on treatments have the potential to improve cognitive function, level of personal and social functioning, negative and positive symptoms, as well as having an improved tolerability profile. Patients enrolled in these studies are asked to donate optional DNA and Non-DNA specimens for pharmacogenetic and genetic research which could provide a better understanding of the effect of these factors on the efficacy, safety, mode of action, progression of schizophrenia and associated diseases. I am also participating in the investigation of a long-acting injectable antipsychotic medication with a 3-month interval for use as maintenance treatment in patients with schizophrenia. The advantage of this long-acting treatment is that its administration would facilitate treatment access and medication adherence among patients with schizophrenia.
Julie Eve Desmarais, Linda Beauclair, Lawrence Annable, Marie-Claire Bélanger, Theodore T. Kolivakis, Howard C. Margolese. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia Therapeutic Advances in Psychopharmacology December 2014, vol. 4 no. 6: 257-267. PMID: 25489477.
Williams R, Chandrasena R, Beauclair L, Luong D, Lam A. Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry of Canada. Neuropsychiatric Disease and Treatment February 2014; Vol. 2014: 417-425. PMCID: PMC3942298.
Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? Desmarais JE, Beauclair L, Margolese HC. J Psychopharmacology, 2012; 26: 1167-1174. PMID: 22651987.
Desmarais JE, Beauclair L, Margolese HC. Switching from brand-name to generic psychotropic medications: a literature review. CNS Neuroscience and Therapeutics, 2011; 17: 750-761 PMID: 21114789.
Margolese HC, Wolf Y, Desmarais JE, Beauclair L: Loss of response after switching from brand-name to generic formulations: 3 cases and a discussion of key clinical considerations when switching. Int Clin Psychopharmacology, 2010 May; 25(3):180-182. PMID: 20216221.